Brief: Odonate Therapeutics Announces Initiation Of Contessa 2 Study Of Tesetaxel
04/03/2019 21:33
March 4 (Reuters) - Odonate Therapeutics Inc ODT.O :
* ODONATE THERAPEUTICS ANNOUNCES INITIATION OF CONTESSA 2, A
PHASE
2 STUDY OF TESETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR
METASTATIC BREAST CANCER WHO HAVE NOT PREVIOUSLY RECEIVED A
TAXANE
* ODONATE THERAPEUTICS INC - CONTESSA 2 WILL INVESTIGATE
COMBINATION OF TESETAXEL PLUS A REDUCED DOSE OF CAPECITABINE
Source text for Eikon: ID:nBw99jBfca
Further company coverage: ODT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Odonate
See all newsBrief: Odonate Announces Expected Delisting Of Its Stock
Brief: Odonate Therapeutics Announces Planned Return Of Capital To Stockholders Through Share Repurchase Plan
Brief: Odonate Therapeutics Announces Quarterly Loss Per Share Of $0.58
Odonate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Odonate Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview